Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients (MAIN-A)
MAINtenance Afinitor: A Randomized Trial Comparing Maintenance Aromatase Inhibitors (AIs) + Everolimus (Afinitor) vs AIs in Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients With Disease Control After First Line Chemotherapy
Sponsor: Istituto Oncologico Veneto IRCCS
This PHASE3 trial investigates Breast Cancer Metastatic and is currently completed. Istituto Oncologico Veneto IRCCS leads this study, which shows 9 recorded versions since 2014 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
-
Oct 2020 — Jan 2021 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
▶ Show 4 earlier versions
-
Oct 2018 — Oct 2020 [monthly]
Active Not Recruiting PHASE3
-
Aug 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE3
First recorded
Jul 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Istituto Oncologico Veneto IRCCS
- University of Padova
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ancona, Italy , Bergamo, Italy , Bologna, Italy , Brescia, Italy , Brindisi, Italy , Catania, Italy , Cona, Italy , Cuneo, Italy , Grosseto, Italy , Mestre, Italy and 6 more locations